Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients.

Zinzani PL, Magagnoli M, Moretti L, Battista R, Ronconi F, De Renzo A, Zaccaria A, Gentilini P, Guardigni L, Gherlinzoni F, Cellini C, Fattori PP, Bendandi M, Bocchia M, Aitini E, Tura S.

Haematologica. 1999 Nov;84(11):1002-6.

2.

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.

Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A, Guardigni L, Mazza P, Marra R, Ronconi F, Lauta VM, Bendandi M, Gherlinzoni F, Gentilini P, Ciccone F, Cellini C, Stefoni V, Ricciuti F, Gobbi M, Tura S.

J Clin Oncol. 2000 Feb;18(4):773-9.

PMID:
10673518
4.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.

Blood. 2004 Nov 15;104(10):3064-71. Epub 2004 Jul 29.

5.

Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.

Bocchia M, Bigazzi C, Marconcini S, Forconi F, Marotta G, Algeri R, Lauria F.

Haematologica. 1999 Aug;84(8):716-20.

6.

[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W.

Dtsch Med Wochenschr. 2002 Oct 25;127(43):2253-8. German.

PMID:
12397539
7.
8.

FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.

Zinzani PL, Bendandi M, Gherlinzoni F, Merla E, Gozzetti A, Tura S.

Haematologica. 1996 Mar-Apr;81(2):168-71.

9.

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG).

Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31.

10.

Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.

Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.

Haematologica. 2000 Dec;85(12):1268-70.

11.

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.

Rummel MJ, Chow KU, Karakas T, Jäger E, Mezger J, von Grünhagen U, Schalk KP, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS.

Eur J Cancer. 2002 Sep;38(13):1739-46.

PMID:
12175690
12.

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF.

Cancer. 2006 Jun 1;106(11):2412-20.

14.

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M.

J Clin Oncol. 2001 Mar 1;19(5):1414-20.

PMID:
11230486
15.

The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.

Eucker J, Schille C, Schmid P, Jakob C, Schetelig J, Kingreen D, Mergenthaler HG, Huhn D, Possinger K, Sezer O.

Anticancer Drugs. 2002 Oct;13(9):907-13.

PMID:
12394253
16.

Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.

Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu AM, Truini M, Rubagotti A, Chisesi T, Vimercati R, Rossi E, Sertoli MR, Mattei D, Marino G, Gobbi M.

Haematologica. 2001 Mar;86(3):282-6.

17.

Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.

Zinzani PL, Pulsoni A, Gentilini P, Visani G, Perrotti A, Molinari AL, Guardigni L, Tani M, Villivà N, Stefoni V, Alinari L, Martelli M, Bonifazi F, Pileri S, Tura S, Baccarani M.

Leuk Lymphoma. 2004 Sep;45(9):1815-9.

PMID:
15223641
18.

[Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].

Huang HQ, Jiang WQ, Peng YL, Xia ZJ, Li YH, Li XB, Lin TY, Sun XF, Guan ZZ.

Ai Zheng. 2004 Apr;23(4):448-51. Chinese.

PMID:
15087037
19.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
20.

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A.

Leuk Lymphoma. 2001 Sep-Oct;42(5):1015-22.

PMID:
11697618
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk